Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ANI Pharmaceuticals (ANIP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.

ANI Pharmaceuticals is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ANIP's full-year earnings has moved 12.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, ANIP has gained about 0.8% so far this year. Meanwhile, stocks in the Medical group have lost about 8.5% on average. This means that ANI Pharmaceuticals is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Adlai Nortye Ltd. Sponsored ADR (ANL). The stock is up 833.1% year-to-date.

Over the past three months, Adlai Nortye Ltd. Sponsored ADR's consensus EPS estimate for the current year has increased 45.8%. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual companies and currently sits at #144 in the Zacks Industry Rank. Stocks in this group have lost about 1.6% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Adlai Nortye Ltd. Sponsored ADR is also part of the same industry.

Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research